Recon: Pfizer posts positive Phase 3 data for RSV vaccine in adults 18 and older; Novartis to cut 680 product development jobs
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States